Patent classifications
A61K31/28
Combination comprising N-acetyl-L-cysteine and its use
A combination of N-acetyl-L-cysteine, selenium in the form of selenomethionine and melatonin, and a medical product or pharmaceutical composition comprising such combination, useful for the treatment of a variety of diseases and conditions is described. The combination of N-acetyl-L-cysteine, selenium in the form of selenomethionine and melatonin is also useful for cosmetic treatment of skin and as an antibacterial agent.
Combination comprising N-acetyl-L-cysteine and its use
A combination of N-acetyl-L-cysteine, selenium in the form of selenomethionine and melatonin, and a medical product or pharmaceutical composition comprising such combination, useful for the treatment of a variety of diseases and conditions is described. The combination of N-acetyl-L-cysteine, selenium in the form of selenomethionine and melatonin is also useful for cosmetic treatment of skin and as an antibacterial agent.
Chromium 4-hydroxyisoleucinate compound methods for prepartion and use
A dietary supplement that may include chromium 4-hydroxyisoleucinate. The chromium 4-hydroxyisoleucinate may be provided in a molar ratio between 1:5 and 5:1 ligand to metal. The dietary supplement may be used to manage blood glucose levels, to improve insulin resistance, and to improve glucose uptake.
Chromium 4-hydroxyisoleucinate compound methods for prepartion and use
A dietary supplement that may include chromium 4-hydroxyisoleucinate. The chromium 4-hydroxyisoleucinate may be provided in a molar ratio between 1:5 and 5:1 ligand to metal. The dietary supplement may be used to manage blood glucose levels, to improve insulin resistance, and to improve glucose uptake.
Anti-cancer agents and methods of use
An anti-cancer agent includes Au(I) purinyl, indolyl, or azaindolyl analogues encapsulated in sterically hindered phosphine ligands.
Anti-cancer agents and methods of use
An anti-cancer agent includes Au(I) purinyl, indolyl, or azaindolyl analogues encapsulated in sterically hindered phosphine ligands.
SYNTHESIS OF NANOCOMPOUNDS COMPRISING ANATASE-PHASE TITANIUM OXIDE AND COMPOSITIONS CONTAINING SAME FOR THE TREATMENT OF CANCER
This invention relates to novel nanocompounds that are cytotoxic to tumor cells when combined with ultraviolet light, the nanocompounds comprising multilayered carbon nanotubes with anatase-phase titanium dioxide or anatase-phase titanium dioxide and folate. The invention also relates to a composition containing said nanocompounds and to a method for the treatment of cancer; comprising the administration of said composition in co-treatment with UV radiation. The invention further relates to a method for the synthesis of the nano-compounds.
A METHOD FOR SIDE EFFECT REDUCTION IN THE USE OF STATINS VIA PHYSIOLOGICALLY SYNTHESIZED GLUTATHIONE
Embodiments of the present invention relate generally the use of certain compositions, e.g., compositions comprising a glutathione precursor and a selenium source, in the therapy of subjects suffering from diseases associated with hyperiipidemia and/or hypercholesterolemia. Related embodiments of the present invention relate to treatment and/or reducing the incidence of the side effects of statin therapy comprising administering to a subject in need, a composition comprising a glutathione precursor and a selenium source. Embodiments of the invention also relate to the use of the compositions in combination therapy with other agents such as statins, cholesterol absorption inhibitors, bile acid binding resins, or fibrates. In other embodiments, the invention relates to the use of such compositions comprising the glutathione precursor and the selenium source in the therapy of subjects suffering from erectile dysfunction and/or viral diseases such as Ebola virus disease (EVD) or Ebola hemorrhagic fever (EHF).
A METHOD FOR SIDE EFFECT REDUCTION IN THE USE OF STATINS VIA PHYSIOLOGICALLY SYNTHESIZED GLUTATHIONE
Embodiments of the present invention relate generally the use of certain compositions, e.g., compositions comprising a glutathione precursor and a selenium source, in the therapy of subjects suffering from diseases associated with hyperiipidemia and/or hypercholesterolemia. Related embodiments of the present invention relate to treatment and/or reducing the incidence of the side effects of statin therapy comprising administering to a subject in need, a composition comprising a glutathione precursor and a selenium source. Embodiments of the invention also relate to the use of the compositions in combination therapy with other agents such as statins, cholesterol absorption inhibitors, bile acid binding resins, or fibrates. In other embodiments, the invention relates to the use of such compositions comprising the glutathione precursor and the selenium source in the therapy of subjects suffering from erectile dysfunction and/or viral diseases such as Ebola virus disease (EVD) or Ebola hemorrhagic fever (EHF).
PREBIOTIC INULIN BASED PREPARATION
The present invention relates to an inulin-based prebiotic complex enriched with vitamin B12 and selenium, which finds use in the field of food, nutraceutical, herbal, pharmaceutical preparations.